DPP4 and atrial fibrillation: Finally, newer diabetes medication classes including glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors that have been associated with cardioprotective effects have not been shown to reduce the incidence of AF [133].